Common Stock, $0.0001 par value per share
- Symbol
- AMLX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Amylyx Pharmaceuticals, Inc.
AMLXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”).…
Press release in this filing
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results →Company context
At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.
Current securities
Registered securities in this filing
AMYLYX PHARMACEUTICALS, INC. · 8-K · Filed 2026-08-06
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”).
The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 amlx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results • Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated in late August or early September 2026 • Cash runway expected to fund operations into 2028 • Management to host conference call and webcast today at 8:00 a.m. Eastern Time CAMBRIDGE, Mass., August 6, 2026 - Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the second quarter ended June 30, 2026. “With the last participant’s final study visit recently completed, we are eagerly anticipating the expected topline data readout of the pivotal Phase 3 LUCIDITY trial in post-bariatric hypoglycemia in late August or early September,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “In parallel, we are continuing to advance our NDA readiness and our pre-commercial work to support a potential submission and commercial launch of avexitide in 2027, if approved. At ENDO in June 2026, we …
Open exhibit ↗